secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001213900-23-083634
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial shareholders approve equity plan amendment increasing authorized shares to 500,000; re-elect directors
--------------------------------------------------------------------------------

- Stockholders approved Amendment No. 5 to 2017 Equity Incentive Plan, increasing shares from 380,000 to 500,000.
- Cary J. Claiborne and Robertson H. Gilliland re-elected as Class II directors for three-year terms.
- Marcum LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/0001213900-23-083634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/ea187742-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-083634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer